SCHEMBL3013408

SCHEMBL3013408

Cc1ccc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.59
NFKB1 P19838 3/20 0.49
NFKB2 Q00653 3/20 0.49
RELA Q04206 3/20 0.49
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 4/20 0.44
USP2 O75604 2/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 4/20 0.43
MAPK1 P28482 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
POLB P06746 2/20 0.41
GBA1 P04062 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005755 0.92 AR (0.59) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3018393 0.91 AR (0.56) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3014924 0.89 AR (0.64) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3017126 0.89 AR (0.58) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3017595 0.89 SMN1; SMN2 (0.49) ARALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3011119 0.88 AR (0.55) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3017569 0.86 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3015256 0.86 AR (0.57) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3015176 0.86 AR (0.57) ARNFKB1NFKB2RELAALDH1A1
SCHEMBL3007683 0.86 AR (0.59) ARNFKB1NFKB2RELAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NFKB1 1767/4885NFKB2 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.